2026 Q1 -tulosraportti
17 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,05%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 51 | - | - | ||
| 50 | - | - | ||
| 401 | - | - | ||
| 882 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·3 t sitten · MuokattuLilly’s Foundayo strains the liver a lot, which is already a problem for overweight people. I find it difficult to see doctors recommend that one over Novo’s pill, which furthermore has several professional reasons and advantages for a first choice. But can Foundayo risk not being approved in the EU at all?
·2 t sittenAs far as I know, there are few cases where Lilly's pill caused liver damage. FDA is investigating whether there is a connection. Remember now that Novo's pill can increase the risk of NAION.
·9 t sittenSo Novo's weight loss pill is on its way to approval in Europe. That will be big. See attached article.
·8 t sittenYou can sign up for free on Novo’s website to receive information about their stock exchange announcements. Then you are updated before the news gets to write about it.
·1 t sittenhttps://www.novonordisk.com/news-and-media/news-and-ir-materials.html Here you can sign up and receive stock exchange announcements directly to your email.
17 t sitten · Muokattu17 t sitten · MuokattuRemember this. It’s going to be absolutely amazing. Kids and teenagers don’t know it yet, but they’ll definitely embrace it and lie awake at night thinking about it—and about all the amazing changes it will bring to their lives. The NOVO TEEN diabetes pill is coming to market and will make headlines all across America. As the first mover as usual, Novo will become the king of all age groups. Spring 2027: I welcome you, Novo welcomes you, and America will welcome you with open arms to help their children. You will receive it first, then Europe, and later Asia will also celebrate you. All children with diabetes will cry with heartfelt laughter and smile at each other and their parents with joyful happiness. P.S. A glass of wine or two makes wonder and the wonder is real. Bless you Novo for helping so many people around the world. Nighty nights and may Novo bless you haha ;p And for gods sake to all of you who sits with losses like I did, go buy some US tech related stocks. Next friday there's a chance of a bigger dip to occur due to inflation report coming out at 14:30 danish time and other stuff going on that day. Here's a few to start of with: SNDK, MU, INTC, KLA, LITE, MRVL, AMD, NVDA, STX, WDC and ASML from Holland. All the best and good luck.
·10 t sittenThat type 2 diabetes is seen among children is extremely sad and says a lot about the food products we all encounter in supermarkets and fast-food chains. No doubt that certain tech stocks have done well and others have not. Your post seems more like a mockery of Novo, more as if you are affected and emotionally out of balance. Who says that the rest of us don't already own tech stocks? Personally, I am inspired by people like Warren Buffett, Howard Marks etc. However, somewhat contrary to Warren Buffett's thoughts, I actually have many different stocks (and Berkshire Hathaway actually does too) but yes, some make up more than others. The point is that for my already existing portfolio, I often add what I find undervalued, and this is where Novo comes into the picture. Growth stocks are certainly often good investments, and thus they are also in several of my portfolios, but when the market throws a stock like Novo at me with that valuation and with that pipeline, where the valuation is even lower than after the financial crisis due to fear of the weight loss area, and they are just around the corner sending Wegovy in pill form to the market which is now surging, where Cagrisema is coming to market soon and later Amycretin (hopefully 2028 and which actually gives approx. 24% weight loss in just 36 weeks and continues weight loss in subsequent weeks, but not yet published figures) Then I strike, because as an investor I am not focused on the here and now, but on the future I believe is coming. I see Novo with the best products, where they are currently losing on weight loss for injection, and that has twisted investors' heads. Something I and some others said back in 2024. Eli Lilly was the king of injection (but they will soon lose that position) and Novo is already the king of pill form. But yes, Novo has pulled down the portfolio, but if I am right in my analysis, the share price increase will come at some point.·4 t sitten · MuokattuI have incidentally been employed at Novo in connection with projects in France, USA and Brazil many years ago and was very happy with my work while it lasted, so I will never ever mock Novo or people who are invested in Novo in various ways in any way whatsoever, as you prejudicially think I do. I am precisely very enthusiastic about Novo and all the good deeds that the company creates out in the big world and have myself contributed to it as an employee.
·22 t sitten · MuokattuIt can be dangerous to stare oneself blind in prescriptions at Novo . That often occurs among many eager inexperienced writers ! Try to investigate - how large discounts Novo will have to give in the coming time . If one has a knack for research and is good at English, discounts are highlighted in several places . When the prescription number stagnates - one can be disappointed .One suddenly feels the hype has been too strong. Regarding Cagrisema which Helge wrote about last night and judged it to be hopeless . It is actually still in play and that is indeed pleasing. ( further research ) Novo has tightened up and that is probably due to the new CEO , Q2 will be difficult .Don't set expectations too high. But if everything goes well ( large expenses ) . Q4 could end at 350 PS I don't like that the writer encourages muting me for spam .- ·1 päivä sittenOral Wegovy reached 142,959 prescriptions, up from 137,333 the week before. Foundayo reached 16,698 prescriptions in week 6, up from 10,248 in week 5. In comparison, oral Wegovy was already up to 56,943 prescriptions in its own week 6.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
17 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,05%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sitten · MuokattuLilly’s Foundayo strains the liver a lot, which is already a problem for overweight people. I find it difficult to see doctors recommend that one over Novo’s pill, which furthermore has several professional reasons and advantages for a first choice. But can Foundayo risk not being approved in the EU at all?·2 t sittenAs far as I know, there are few cases where Lilly's pill caused liver damage. FDA is investigating whether there is a connection. Remember now that Novo's pill can increase the risk of NAION.
- ·9 t sittenSo Novo's weight loss pill is on its way to approval in Europe. That will be big. See attached article.·8 t sittenYou can sign up for free on Novo’s website to receive information about their stock exchange announcements. Then you are updated before the news gets to write about it.·1 t sittenhttps://www.novonordisk.com/news-and-media/news-and-ir-materials.html Here you can sign up and receive stock exchange announcements directly to your email.
- 17 t sitten · Muokattu17 t sitten · MuokattuRemember this. It’s going to be absolutely amazing. Kids and teenagers don’t know it yet, but they’ll definitely embrace it and lie awake at night thinking about it—and about all the amazing changes it will bring to their lives. The NOVO TEEN diabetes pill is coming to market and will make headlines all across America. As the first mover as usual, Novo will become the king of all age groups. Spring 2027: I welcome you, Novo welcomes you, and America will welcome you with open arms to help their children. You will receive it first, then Europe, and later Asia will also celebrate you. All children with diabetes will cry with heartfelt laughter and smile at each other and their parents with joyful happiness. P.S. A glass of wine or two makes wonder and the wonder is real. Bless you Novo for helping so many people around the world. Nighty nights and may Novo bless you haha ;p And for gods sake to all of you who sits with losses like I did, go buy some US tech related stocks. Next friday there's a chance of a bigger dip to occur due to inflation report coming out at 14:30 danish time and other stuff going on that day. Here's a few to start of with: SNDK, MU, INTC, KLA, LITE, MRVL, AMD, NVDA, STX, WDC and ASML from Holland. All the best and good luck.·10 t sittenThat type 2 diabetes is seen among children is extremely sad and says a lot about the food products we all encounter in supermarkets and fast-food chains. No doubt that certain tech stocks have done well and others have not. Your post seems more like a mockery of Novo, more as if you are affected and emotionally out of balance. Who says that the rest of us don't already own tech stocks? Personally, I am inspired by people like Warren Buffett, Howard Marks etc. However, somewhat contrary to Warren Buffett's thoughts, I actually have many different stocks (and Berkshire Hathaway actually does too) but yes, some make up more than others. The point is that for my already existing portfolio, I often add what I find undervalued, and this is where Novo comes into the picture. Growth stocks are certainly often good investments, and thus they are also in several of my portfolios, but when the market throws a stock like Novo at me with that valuation and with that pipeline, where the valuation is even lower than after the financial crisis due to fear of the weight loss area, and they are just around the corner sending Wegovy in pill form to the market which is now surging, where Cagrisema is coming to market soon and later Amycretin (hopefully 2028 and which actually gives approx. 24% weight loss in just 36 weeks and continues weight loss in subsequent weeks, but not yet published figures) Then I strike, because as an investor I am not focused on the here and now, but on the future I believe is coming. I see Novo with the best products, where they are currently losing on weight loss for injection, and that has twisted investors' heads. Something I and some others said back in 2024. Eli Lilly was the king of injection (but they will soon lose that position) and Novo is already the king of pill form. But yes, Novo has pulled down the portfolio, but if I am right in my analysis, the share price increase will come at some point.·4 t sitten · MuokattuI have incidentally been employed at Novo in connection with projects in France, USA and Brazil many years ago and was very happy with my work while it lasted, so I will never ever mock Novo or people who are invested in Novo in various ways in any way whatsoever, as you prejudicially think I do. I am precisely very enthusiastic about Novo and all the good deeds that the company creates out in the big world and have myself contributed to it as an employee.
- ·22 t sitten · MuokattuIt can be dangerous to stare oneself blind in prescriptions at Novo . That often occurs among many eager inexperienced writers ! Try to investigate - how large discounts Novo will have to give in the coming time . If one has a knack for research and is good at English, discounts are highlighted in several places . When the prescription number stagnates - one can be disappointed .One suddenly feels the hype has been too strong. Regarding Cagrisema which Helge wrote about last night and judged it to be hopeless . It is actually still in play and that is indeed pleasing. ( further research ) Novo has tightened up and that is probably due to the new CEO , Q2 will be difficult .Don't set expectations too high. But if everything goes well ( large expenses ) . Q4 could end at 350 PS I don't like that the writer encourages muting me for spam .
- ·1 päivä sittenOral Wegovy reached 142,959 prescriptions, up from 137,333 the week before. Foundayo reached 16,698 prescriptions in week 6, up from 10,248 in week 5. In comparison, oral Wegovy was already up to 56,943 prescriptions in its own week 6.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 51 | - | - | ||
| 50 | - | - | ||
| 401 | - | - | ||
| 882 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
17 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,05%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·3 t sitten · MuokattuLilly’s Foundayo strains the liver a lot, which is already a problem for overweight people. I find it difficult to see doctors recommend that one over Novo’s pill, which furthermore has several professional reasons and advantages for a first choice. But can Foundayo risk not being approved in the EU at all?·2 t sittenAs far as I know, there are few cases where Lilly's pill caused liver damage. FDA is investigating whether there is a connection. Remember now that Novo's pill can increase the risk of NAION.
- ·9 t sittenSo Novo's weight loss pill is on its way to approval in Europe. That will be big. See attached article.·8 t sittenYou can sign up for free on Novo’s website to receive information about their stock exchange announcements. Then you are updated before the news gets to write about it.·1 t sittenhttps://www.novonordisk.com/news-and-media/news-and-ir-materials.html Here you can sign up and receive stock exchange announcements directly to your email.
- 17 t sitten · Muokattu17 t sitten · MuokattuRemember this. It’s going to be absolutely amazing. Kids and teenagers don’t know it yet, but they’ll definitely embrace it and lie awake at night thinking about it—and about all the amazing changes it will bring to their lives. The NOVO TEEN diabetes pill is coming to market and will make headlines all across America. As the first mover as usual, Novo will become the king of all age groups. Spring 2027: I welcome you, Novo welcomes you, and America will welcome you with open arms to help their children. You will receive it first, then Europe, and later Asia will also celebrate you. All children with diabetes will cry with heartfelt laughter and smile at each other and their parents with joyful happiness. P.S. A glass of wine or two makes wonder and the wonder is real. Bless you Novo for helping so many people around the world. Nighty nights and may Novo bless you haha ;p And for gods sake to all of you who sits with losses like I did, go buy some US tech related stocks. Next friday there's a chance of a bigger dip to occur due to inflation report coming out at 14:30 danish time and other stuff going on that day. Here's a few to start of with: SNDK, MU, INTC, KLA, LITE, MRVL, AMD, NVDA, STX, WDC and ASML from Holland. All the best and good luck.·10 t sittenThat type 2 diabetes is seen among children is extremely sad and says a lot about the food products we all encounter in supermarkets and fast-food chains. No doubt that certain tech stocks have done well and others have not. Your post seems more like a mockery of Novo, more as if you are affected and emotionally out of balance. Who says that the rest of us don't already own tech stocks? Personally, I am inspired by people like Warren Buffett, Howard Marks etc. However, somewhat contrary to Warren Buffett's thoughts, I actually have many different stocks (and Berkshire Hathaway actually does too) but yes, some make up more than others. The point is that for my already existing portfolio, I often add what I find undervalued, and this is where Novo comes into the picture. Growth stocks are certainly often good investments, and thus they are also in several of my portfolios, but when the market throws a stock like Novo at me with that valuation and with that pipeline, where the valuation is even lower than after the financial crisis due to fear of the weight loss area, and they are just around the corner sending Wegovy in pill form to the market which is now surging, where Cagrisema is coming to market soon and later Amycretin (hopefully 2028 and which actually gives approx. 24% weight loss in just 36 weeks and continues weight loss in subsequent weeks, but not yet published figures) Then I strike, because as an investor I am not focused on the here and now, but on the future I believe is coming. I see Novo with the best products, where they are currently losing on weight loss for injection, and that has twisted investors' heads. Something I and some others said back in 2024. Eli Lilly was the king of injection (but they will soon lose that position) and Novo is already the king of pill form. But yes, Novo has pulled down the portfolio, but if I am right in my analysis, the share price increase will come at some point.·4 t sitten · MuokattuI have incidentally been employed at Novo in connection with projects in France, USA and Brazil many years ago and was very happy with my work while it lasted, so I will never ever mock Novo or people who are invested in Novo in various ways in any way whatsoever, as you prejudicially think I do. I am precisely very enthusiastic about Novo and all the good deeds that the company creates out in the big world and have myself contributed to it as an employee.
- ·22 t sitten · MuokattuIt can be dangerous to stare oneself blind in prescriptions at Novo . That often occurs among many eager inexperienced writers ! Try to investigate - how large discounts Novo will have to give in the coming time . If one has a knack for research and is good at English, discounts are highlighted in several places . When the prescription number stagnates - one can be disappointed .One suddenly feels the hype has been too strong. Regarding Cagrisema which Helge wrote about last night and judged it to be hopeless . It is actually still in play and that is indeed pleasing. ( further research ) Novo has tightened up and that is probably due to the new CEO , Q2 will be difficult .Don't set expectations too high. But if everything goes well ( large expenses ) . Q4 could end at 350 PS I don't like that the writer encourages muting me for spam .
- ·1 päivä sittenOral Wegovy reached 142,959 prescriptions, up from 137,333 the week before. Foundayo reached 16,698 prescriptions in week 6, up from 10,248 in week 5. In comparison, oral Wegovy was already up to 56,943 prescriptions in its own week 6.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 51 | - | - | ||
| 50 | - | - | ||
| 401 | - | - | ||
| 882 | - | - | ||
| 35 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt